Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

sell psoriasis drug@

WASHINGTON, Nov 15 (Reuters) - Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. (Reporting by Diane Bartz; Editing by Sandra Maler)